07.11.2012 • News

Hospira Posts Quarterly Profit Vs Year-Ago Loss

Hospira on Wednesday posted a net profit for the third quarter compared with a year-earlier loss as sales rose slightly, and backed its outlook for the full year.

Net earnings were $1.2 million, or 1 cent per share, versus a net loss of $88.9 million, or 54 cents per share, in the 2011 quarter.

Excluding items, earnings were 47 Cents per share. On that basis, analysts on average were expecting earnings of 45 cents.

Sales rose 1.8% to $994.0 million from $976.7 million a year before.

Hospira, a maker of specialty injectable pharmaceuticals and drug pumps, said it continues to expect 2012 net sales to show a fall of 1% to a rise of 2%, excluding the impact of foreign currency.

It forecast full-year earnings per share, excluding items, of $2.00.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read